NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with the National Cancer Institute (NCI), in addition to agreements with three other unnamed academic and pharma groups, to demonstrate the clinical utility of Cofactor's RNA-based immune-profiling assay, Cofactor Paragon.

Under the terms of their material transfer agreement, the collaborators will use clinical specimens from several of NCI's clinical trials to validate the Paragon assay.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.